Arvind Chaudhry
Impact in
Papers in
- Oncology 24
- Cancer Immunotherapy and Biomarkers 11
- CAR-T cell therapy research 8
- HER2/EGFR in Cancer Research 6
- Co-authors
- Keiko Funa (3 shared papers)Kjell Öberg (2 shared papers)C H Heldin (1 shared paper)Anders Gobl (1 shared paper)Carl‐Henrik Heldin (1 shared paper)Younong Xu (3 shared papers)Britt Skogseid (1 shared paper)A Gobl (1 shared paper)
- Journals
- Journal of Clinical Oncology (17 papers)Annals of Oncology (5 papers)Blood (3 papers)Cancer Research (2 papers)Cancer Immunology Immunotherapy (2 papers)
- Partner nations
- United StatesChinaPoland
In The Last Decade
Arvind Chaudhry
43 papers receiving 665 citations
Peers
Comparison fields: 5 of 59
- Oncology 445
- Neurology 140
- Epidemiology 246
- Immunology 144
- Physiology 24
Countries citing papers authored by Arvind Chaudhry
This map shows the geographic impact of Arvind Chaudhry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arvind Chaudhry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arvind Chaudhry more than expected).
Fields of papers citing papers by Arvind Chaudhry
This network shows the impact of papers produced by Arvind Chaudhry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arvind Chaudhry. The network helps show where Arvind Chaudhry may publish in the future.
Co-authors
The 25 scholars most cited alongside Arvind Chaudhry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. | 1992 | 98 |
| 2 | 1993 | 93 | |
| 3 | 2013 | 68 | |
| 4 | Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. | 1995 | 62 |
| 5 | Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. | 1999 | 49 |
| 6 | Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors. | 1994 | 40 |
| 7 | 2016 | 37 | |
| 8 | 2015 | 37 | |
| 9 | 2022 | 30 | |
| 10 | 2019 | 27 | |
| 11 | 2024 | 14 | |
| 12 | 2020 | 11 | |
| 13 | 1996 | 10 | |
| 14 | 2021 | 10 | |
| 15 | 2020 | 9 | |
| 16 | 2021 | 8 | |
| 17 | 2021 | 7 | |
| 18 | 2021 | 7 | |
| 19 | 2018 | 6 | |
| 20 | 2023 | 6 |
About Arvind Chaudhry
Arvind Chaudhry is a scholar working on Oncology, Molecular Biology, Genetics, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 46 papers that have together received 684 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (11 papers), Chronic Lymphocytic Leukemia Research (10 papers), CAR-T cell therapy research (8 papers), HER2/EGFR in Cancer Research (6 papers), Immunotherapy and Immune Responses (6 papers), Lymphoma Diagnosis and Treatment (5 papers), Neuroendocrine Tumor Research Advances (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). The work is most often cited by research in Oncology (445 citations), Neurology (140 citations), Epidemiology (246 citations), Immunology (144 citations) and Physiology (24 citations). Arvind Chaudhry has collaborated with scholars based in United States, China and Poland. Frequent co-authors include Keiko Funa, Kjell Öberg, C H Heldin, Anders Gobl, Carl‐Henrik Heldin, Younong Xu, Britt Skogseid, A Gobl, Joseph P. Balint and Michael A. Morse. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Blood, Cancer Research and Cancer Immunology Immunotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.